Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CTSV | O60911 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.44 |
| ▸ | MGMT | P16455 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30501940 | 1.00 | POLB (0.46) | POLBMEN1KMT2AMAPTCTSV | |
| SCHEMBL5591435 | 0.86 | MGMT (0.46) | MEN1KMT2AMAPTMGMTCYP19A1 | |
| SCHEMBL28521933 | 0.85 | PIN1 (0.49) | POLBMEN1KMT2AMAPTCTSV | |
| SCHEMBL5241194 | 0.85 | MAPT (0.48) | POLBMEN1KMT2AMAPTCTSV | |
| SCHEMBL5902009 | 0.83 | CTSV (0.47) | POLBMEN1KMT2AMAPTCTSV | |
| SCHEMBL1583614 | 0.83 | POLB (0.48) | POLBMEN1KMT2AMAPTCTSV | |
| SCHEMBL31473699 | 0.83 | POLB (0.57) | POLBMEN1KMT2AMAPTCTSV | |
| SCHEMBL29751809 | 0.83 | POLB (0.48) | POLBMEN1KMT2AMAPTCTSV | |
| SCHEMBL1312167 | 0.83 | POLB (0.57) | POLBMEN1KMT2AMAPTCTSV | |
| SCHEMBL16427372 | 0.83 | MEN1 (0.55) | POLBMEN1KMT2AMAPTCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114249694-B | In terglazan Process for the preparation of intermediates | 浙江四维医药科技有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-119638631-A | Preparation method of key intermediate of agoraphobia | 安徽皓元药业有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-114249694-A | Preparation method of texas intermediate | 浙江四维医药科技有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-10005774-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005774-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| EP-3027601-B1 | SYK INHIBITORS | GILEAD SCIENCES INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20160368918-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-12-22 | — | — | US | disclosed |
| US-20160368918-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-12-22 | — | — | US | disclosed |
| US-9376441-B2 | Substituted pyrrolidines as SYK inhibitors | GILEAD SCIENCES, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376441-B2 | Substituted pyrrolidines as SYK inhibitors | GILEAD SCIENCES, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| EP-1756067-A1 | 7-SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS INHIBITORS OF GASTRIC ACID SECRETION | Altana Pharma AG (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-20060194969-A1 | 4-Substituted benzimidazoles and their uses as inhibitors of gastric secretion | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | disclosed |
| US-20060194968-A1 | Cyclic benizimidazoles | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | disclosed |
| CN-1764662-A | Cyclic benzimidazoles. | ALTANA PHARMA AG (DE) | 2006-04-26 | — | — | CN | disclosed |
| EP-1613626-A1 | CYCLIC BENZIMIDAZOLES | ALTANA Pharma AG (DE) | 2006-01-11 | — | — | EP | disclosed |
| CN-1720236-A | 4-substituted benzimidazoles and their use as gastric secretion inhibitors | ALTANA PHARMA AG (DE) | 2006-01-11 | — | — | CN | disclosed |
| WO-2005111000-A1 | 7-SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS INHIBITORS OF GASTRIC ACID SECRETION | ALTANA PHARMA AG (DE) | 2005-11-24 | — | — | WO | disclosed |
| EP-1575924-A1 | 4-SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS INHIBITORS OF GASTRIC SECRETION | ALTANA Pharma AG (DE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004087701-A1 | CYCLIC BENZIMIDAZOLES | ALTANA PHARMA AG (DE) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004054984-A1 | 4-SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS INHIBITORS OF GASTRIC SECRETION | ALTANA PHARMA AG (DE) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194968-A1 | Cyclic benizimidazoles | VIP, SI, GIPR | POLB 3725/4885MEN1 3164/4885KMT2A 3220/4885 |
| US-20060194969-A1 | 4-Substituted benzimidazoles and their uses as inhibitors of gastric secretion | GIPR, VIP, SI | POLB 4645/4885MEN1 2551/4885KMT2A 4095/4885 |
| US-20160368918-A1 | SYK INHIBITORS | SYK, BTK, LYN | POLB 3783/4885MEN1 3190/4885KMT2A 930/4885 |
| US-10005774-B2 | Syk inhibitors | SYK, BTK, LYN | POLB 3783/4885MEN1 3190/4885KMT2A 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.